- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00014001
CATIE- 정신분열증 임상시험
정신분열증 환자에 대한 항정신병 약물의 비교 효과(CATIE 정신분열증 임상시험)
연구 개요
상태
정황
상세 설명
이 시험은 제한된 효능 또는 내약성의 이유로 약물 변경이 필요할 수 있는 정신분열증 환자 1,600명으로 구성됩니다. 모든 환자는 연구 참여를 통해 심리사회적 치료를 받게 됩니다. 연구 참가자와 그 가족은 질병에 대한 환자와 가족의 이해를 개선하고, 가족의 질병 부담을 줄이고, 치료 순응도를 최대화하고, 재발을 최소화하고, 다양한 지역사회 기반 재활 서비스에 대한 접근성을 높이고, 학습 유지 개선.
1단계: 환자는 최대 18개월 동안 5가지 치료 조건 중 하나에 무작위로 배정됩니다.
- 320명이 페르페나진(PER)으로 이중맹검 치료 시작
- 320명이 올란자핀(OLZ)으로 이중맹검 치료 시작
- 320명이 퀘티아핀(QUET)으로 이중맹검 치료 시작
- 320명이 리스페리돈(RIS)으로 이중맹검 치료 시작
- 220명이 지프라시돈(ZIP)으로 이중맹검 치료 시작
1상: 100명의 환자를 스크리닝하고 지연성 운동이상증이 있는 것으로 밝혀졌으나 달리 연구에 적격인 경우 1상에서 4가지 비정형 약물 중 하나에 무작위로 배정됩니다.
1상: 1상에서 페르페나진 치료에 실패한 환자는 1상에서 올란자핀, 퀘티아핀 또는 리스페리돈에 무작위로 배정됩니다.
2상: 비투여적 이유로 1상, 1A 또는 1B상에서 처음 할당된 비정형 항정신병 치료를 중단한 환자는 두 번째 할당된 치료(IB상 환자의 경우 세 번째)로 진행하고 나머지 기간까지 추적하게 됩니다. 그들의 18개월 참여는 다음과 같습니다.
- 원래 새로운 비정형 항정신병약 중 하나에 배정되어 효능 실패로 중단된 환자는 이전에 받지 않은 다른 두 가지 새로운 비정형 항정신병약(OLZ, RIS, QUET) 중 하나(50% ) 또는 오픈 라벨 클로자핀(50%).
- 내약성 실패로 인해 중단한 새로운 비정형 항정신병약 중 하나에 원래 배정된 환자는 이전에 받지 않은 다른 새로운 비정형 항정신병약(OLZ, RIS, QUET) 중 하나를 사용한 이중 맹검 치료에 무작위로 배정됩니다(50%). , 또는 지프라시돈(50%)과 함께. 지프라시돈이 활성화될 때까지 모든 환자는 다른 비정형 항정신병약 중 하나에 배정됩니다.
임상 2상은 참가자가 18개월 이상 연구에 참여하더라도 최소 6개월 동안 지속됩니다.
3상: 2상을 중단하는 환자는 연구에서 치료 이력을 기반으로 선호 요법으로 개방 치료를 권장받을 것입니다. 치료 옵션에는 클로자핀, 새로운 비정형 항정신병제(올란자핀, 리스페리돈, 퀘티아핀, 지프라지돈 및 아리피프라졸), 플루페나진 데카노에이트, 페르페나진 및 이러한 약물 중 두 가지를 사용하는 이중 항정신병 요법이 포함됩니다.
참고: 클로자핀을 제외한 모든 치료는 치료 1상 및 2상에서 이중맹검됩니다.
연구 유형
등록
단계
- 4단계
연락처 및 위치
연구 장소
-
-
California
-
Chula Vista, California, 미국, 91910
- Synergy Clinical Research
-
Los Angeles, California, 미국, 90033
- LA County-University of Southern California Medical Center
-
Orange, California, 미국, 92868
- University of California, Irvine
-
San Diego, California, 미국, 92161
- University of California,San Diego/VA Medical System
-
Stanford, California, 미국, 94305
- Stanford University School of Medicine
-
Torrance, California, 미국, 90502
- Harbor UCLA Research & Education Institute
-
-
Connecticut
-
New Britain, Connecticut, 미국, 06050
- New Britain General Hospital
-
New Haven, Connecticut, 미국, 06519
- Yale University/Connecticut Mental Health Center
-
-
Florida
-
Boca Raton, Florida, 미국, 33432
- Mental Health Advocates Inc.
-
Miami, Florida, 미국, 33125
- VA Medical Center
-
Miami, Florida, 미국, 33316
- University of Miami School of Medicine
-
-
Georgia
-
Atlanta, Georgia, 미국, 30319
- Emory University School of Medicine
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- The Queen's Medical Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60634
- Northwestern Medical School Department of Psychiatry
-
Springfield, Illinois, 미국, 62702
- Southern Illinois University School of Medicine
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa Hospital
-
-
Kansas
-
Wichita, Kansas, 미국, 67214
- Psychiatric Research Institute, Outpatient Clinic
-
-
Louisiana
-
Shreveport, Louisiana, 미국, 71130
- Louisiana State University Health Services Center
-
-
Maryland
-
Glen Burnie, Maryland, 미국, 21061
- Clinical Insights, Inc.
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02135
- St. Elizabeth's Medical Center
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital-Freedom Trial Clinic Schizophrenia Program
-
Fall River, Massachusetts, 미국, 02720
- Corrigan Mental Health Center
-
Worcester, Massachusetts, 미국, 01605
- University of Massachusetts Memorial Health Care
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55454
- University of Minnesota School of Medicine
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- University of Mississippi VA Medical Center
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- University of Missouri Kansas City Medical School
-
Springfield, Missouri, 미국, 65802
- Burrell Behavioral Health-Cox North Hospital
-
St. Louis, Missouri, 미국, 63112
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87124
- Albuquerque VA Medical Center
-
-
New York
-
Bronx, New York, 미국, 10468
- Mount Sinai Medical Center-Bronx VA Medical Center
-
Brooklyn, New York, 미국, 11203
- SUNY Downstate Medical Center
-
New York, New York, 미국, 10029
- Mount Sinai Medical Center
-
Rochester, New York, 미국, 14620
- University of Rochester Medical Center
-
Staten Island, New York, 미국, 10305
- Staten Island University Hospital
-
-
North Carolina
-
Butner, North Carolina, 미국, 27509
- Duke University Medical Center-John Umstead Hospital
-
Chapel Hill, North Carolina, 미국, 27599
- University of North Carolina School of Medicine
-
Charlotte, North Carolina, 미국, 28203
- Behavioral Health Center
-
Raleigh, North Carolina, 미국, 27603
- Dorothea Dix Hospital
-
-
Ohio
-
Athens, Ohio, 미국, 45701
- Appalachian Psychiatric Healthcare System
-
Beachwood, Ohio, 미국, 44122
- North East Ohio Health Services
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Philadelphia VA Medical Center
-
Philadelphia, Pennsylvania, 미국, 19131
- Belmont Center For Comprehensive Treatment
-
Philadelphia, Pennsylvania, 미국, 19129
- Eastern Pennsylvania Psychiatric Institute
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29401
- Veterans Affairs Medical Center
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37212
- Vanderbilt University Schizophrenia Research
-
-
Texas
-
Conroe, Texas, 미국, 77304
- Tri-County MHMR Services
-
Dallas, Texas, 미국, 75390
- University of Texas Southwestern Medical Center
-
El Paso, Texas, 미국, 98493
- Life Management Center for MH/MR Services
-
Houston, Texas, 미국, 77030
- Baylor College of Medicine
-
Houston, Texas, 미국, 77092
- MHMRA of Harris County-Northwest Community Service Center
-
San Antonio, Texas, 미국, 78208
- The Center for Health Care Services
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- University of Utah Medical Center
-
Salt Lake City, Utah, 미국, 84117
- Valley Mental Health Psychopharmacology Research Center
-
-
Washington
-
Tacoma, Washington, 미국, 98493
- VA Puget Sound Health Care System
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
포함
- 18-65세
- 정신 분열증의 DSM-IV 진단
- 충분한 동의 능력
제외
- 불내성 또는 치료 중 하나에 대한 반응 실패
- 분열정동장애, 정신지체, 전반적 발달장애, 섬망, 치매, 기억상실증의 진단
- 정신 분열증의 첫 번째 에피소드
- 현재 임신 중이거나 모유 수유 중인 여성
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
공동 작업자 및 조사자
수사관
- 연구 책임자: Jeffrey A Lieberman, MD, University of North Carolina
간행물 및 유용한 링크
일반 간행물
- Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull. 2003;29(1):73-80. doi: 10.1093/oxfordjournals.schbul.a006993.
- Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull. 2003;29(1):45-55. doi: 10.1093/oxfordjournals.schbul.a006990.
- Lieberman JA, Stroup TS. Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care? Schizophr Bull. 2003;29(1):1-6. doi: 10.1093/oxfordjournals.schbul.a006979. No abstract available.
- Rosenheck R, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull. 2003;29(1):81-93. doi: 10.1093/oxfordjournals.schbul.a006994.
- Sernyak MJ, Leslie D, Rosenheck R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry. 2003 Feb;160(2):310-5. doi: 10.1176/appi.ajp.160.2.310.
- Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29(1):15-31. doi: 10.1093/oxfordjournals.schbul.a006986.
- Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 2003;29(1):33-43. doi: 10.1093/oxfordjournals.schbul.a006989.
- Stroup TS, Appelbaum PS. Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Schizophr Bull. 2006 Jan;32(1):147-52. doi: 10.1093/schbul/sbj026. Epub 2005 Nov 10.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19. Erratum In: N Engl J Med. 2010 Sep 9;363(11):1092-3.
- McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 Apr;163(4):600-10. doi: 10.1176/ajp.2006.163.4.600.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006 Apr;163(4):611-22. doi: 10.1176/ajp.2006.163.4.611.
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006 Dec;163(12):2080-9. doi: 10.1176/ajp.2006.163.12.2080.
- Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006 Dec;163(12):2090-5. doi: 10.1176/ajp.2006.163.12.2090.
- Fabbri C, Leggio GM, Drago F, Serretti A. Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia. Mol Genet Genomic Med. 2022 Jun;10(6):e1942. doi: 10.1002/mgg3.1942. Epub 2022 Apr 30.
- Beaudoin M, Hudon A, Giguere CE, Potvin S, Dumais A. Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenia (Heidelb). 2022 Mar 21;8(1):29. doi: 10.1038/s41537-022-00236-w.
- Miller BJ, McEvoy JP, McCall WV. Insomnia, Suicidal Ideation, and Suicide Attempts in the Clinical Antipsychotic Trials of Intervention Effectiveness. J Clin Psychiatry. 2021 Mar 23;82(3):20m13338. doi: 10.4088/JCP.20m13338.
- Pathak S, Jiang Y, DiPetrillo L, Todtenkopf MS, Liu Y, Correll CU. Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study. J Clin Psychiatry. 2020 Mar 17;81(2):19m12731. doi: 10.4088/JCP.19m12731.
- Ozzoude M, Nakajima S, Plitman E, Chung JK, Kim J, Iwata Y, Caravaggio F, Takeuchi H, Uchida H, Graff-Guerrero A, Gerretsen P. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:207-213. doi: 10.1016/j.pnpbp.2018.08.033. Epub 2018 Aug 30.
- Van Dyke P, Thomas KL. Concomitant calcium channel blocker and antipsychotic therapy in patients with schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data. Ann Clin Psychiatry. 2018 Feb;30(1):6-16.
- Xavier RM, Pan W, Dungan JR, Keefe RSE, Vorderstrasse A. Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. Schizophr Res. 2018 Mar;193:83-90. doi: 10.1016/j.schres.2017.07.002. Epub 2017 Jul 8.
- Bahorik AL, Greeno CG, Cochran G, Cornelius JR, Eack SM. Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. Psychiatry Res. 2017 Jul;253:391-397. doi: 10.1016/j.psychres.2017.04.012. Epub 2017 Apr 5.
- Moodie EE, Karran JC, Shortreed SM. A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality. Trials. 2016 May 14;17(1):242. doi: 10.1186/s13063-016-1368-3.
- Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. J Clin Psychiatry. 2015 Nov;76(11):1535-45. doi: 10.4088/JCP.14m09320.
- Takeuchi H, Fervaha G, Remington G. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. J Clin Psychopharmacol. 2015 Dec;35(6):728-30. doi: 10.1097/JCP.0000000000000424. No abstract available.
- Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. J Clin Psychopharmacol. 2015 Apr;35(2):128-33. doi: 10.1097/JCP.0000000000000286.
- Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-being. J Nerv Ment Dis. 2015 Mar;203(3):187-93. doi: 10.1097/NMD.0000000000000266.
- Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. Antipsychotics and amotivation. Neuropsychopharmacology. 2015 May;40(6):1539-48. doi: 10.1038/npp.2015.3. Epub 2015 Jan 8.
- Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-rated and clinician-rated illness severity in schizophrenia. J Clin Psychiatry. 2015 Jul;76(7):924-30. doi: 10.4088/JCP.14m09128.
- Fervaha G, Zakzanis KK, Foussias G, Graff-Guerrero A, Agid O, Remington G. Motivational deficits and cognitive test performance in schizophrenia. JAMA Psychiatry. 2014 Sep;71(9):1058-65. doi: 10.1001/jamapsychiatry.2014.1105.
- Marques TR, Levine SZ, Reichenberg A, Kahn R, Derks EM, Fleischhacker WW, Rabinowitz J, Kapur S. How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses. Eur Neuropsychopharmacol. 2014 Aug;24(8):1279-88. doi: 10.1016/j.euroneuro.2014.04.001. Epub 2014 Apr 24.
- Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand. 2014 Oct;130(4):290-9. doi: 10.1111/acps.12289. Epub 2014 May 22.
- Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. Eur Neuropsychopharmacol. 2014 Jul;24(7):1078-85. doi: 10.1016/j.euroneuro.2014.03.001. Epub 2014 Mar 15.
- Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophr Res. 2014 Apr;154(1-3):89-92. doi: 10.1016/j.schres.2014.02.013. Epub 2014 Mar 11.
- Witt K, Hawton K, Fazel S. The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset. Schizophr Res. 2014 Apr;154(1-3):61-7. doi: 10.1016/j.schres.2014.02.001. Epub 2014 Feb 26.
- Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Gronte D, Remington G. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. J Clin Psychiatry. 2014 May;75(5):506-11. doi: 10.4088/JCP.13m08695.
- Bahorik AL, Newhill CE, Queen CC, Eack SM. Letter to the editor: Critique of Bahorik et al. (2013)--'Underreporting of drug use among individuals with schizophrenia: prevalence and predictors'--a reply. Psychol Med. 2014 Feb;44(3):670-1. doi: 10.1017/s0033291713002560. No abstract available.
- Laber EB, Lizotte DJ, Ferguson B. Set-valued dynamic treatment regimes for competing outcomes. Biometrics. 2014 Mar;70(1):53-61. doi: 10.1111/biom.12132. Epub 2014 Jan 8.
- Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophr Res. 2013 Dec;151(1-3):203-8. doi: 10.1016/j.schres.2013.10.021. Epub 2013 Nov 1.
- Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. Am J Psychiatry. 2013 Sep;170(9):1061-2. doi: 10.1176/appi.ajp.2013.13010060. No abstract available.
- Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophr Res. 2013 Nov;150(2-3):373-9. doi: 10.1016/j.schres.2013.08.033. Epub 2013 Sep 9. Erratum In: Schizophr Res. 2015 Mar;162(1-3):296.
- Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:178-82. doi: 10.1016/j.pnpbp.2013.05.010. Epub 2013 May 29.
- Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia. Eur Neuropsychopharmacol. 2013 Sep;23(9):1072-7. doi: 10.1016/j.euroneuro.2012.11.009. Epub 2012 Dec 9.
- Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res. 2012 May;137(1-3):141-6. doi: 10.1016/j.schres.2012.01.014. Epub 2012 Feb 7.
- Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013 May;39(3):564-74. doi: 10.1093/schbul/sbr189. Epub 2012 Jan 30.
- Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011 Dec;133(1-3):42-6. doi: 10.1016/j.schres.2011.09.018. Epub 2011 Oct 14.
- Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011 Jan;72(1):75-80. doi: 10.4088/JCP.09m05258gre. Epub 2010 Sep 21.
- Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA; CATIE Investigators. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011 Mar;72(3):295-303. doi: 10.4088/JCP.09m05793yel. Epub 2010 Aug 10.
- Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009 Dec 1;66(11):1013-22. doi: 10.1016/j.biopsych.2009.06.005. Epub 2009 Jul 29.
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- N01 MH090001-06
- DSIR AT (NCT00590863)
- N01MH90001-SZ
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .